Skip to main content
Journal cover image

Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions.

Publication ,  Journal Article
Laskowitz, DT; Vitek, MP
Published in: Pharmacogenomics
August 2007

The apolipoprotein E (apoE) polymorphism is emerging as a uniquely important genetic modifier that affects functional outcome from both acute and chronic neurological injuries. Recent attention has focused on common denominator mechanisms by which apoE might affect brain injury and/or brain repair responses in clinically diverse diseases. Although endogenous apoE likely serves several adaptive functions in the injured CNS, there is growing evidence that its effect on modifying brain inflammatory responses and providing protection from excitotoxic injury may be central to its protective properties. A more complete understanding of the role that apoE plays in the injured brain has led to novel therapeutic strategies for both acute and chronic neurological disease.

Duke Scholars

Published In

Pharmacogenomics

DOI

EISSN

1744-8042

Publication Date

August 2007

Volume

8

Issue

8

Start / End Page

959 / 969

Location

England

Related Subject Headings

  • Polymorphism, Genetic
  • Pharmacology & Pharmacy
  • Pharmacogenetics
  • Nervous System Diseases
  • Inflammation Mediators
  • Humans
  • Cell Death
  • Apolipoproteins E
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Laskowitz, D. T., & Vitek, M. P. (2007). Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions. Pharmacogenomics, 8(8), 959–969. https://doi.org/10.2217/14622416.8.8.959
Laskowitz, Daniel T., and Michael P. Vitek. “Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions.Pharmacogenomics 8, no. 8 (August 2007): 959–69. https://doi.org/10.2217/14622416.8.8.959.
Laskowitz DT, Vitek MP. Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions. Pharmacogenomics. 2007 Aug;8(8):959–69.
Laskowitz, Daniel T., and Michael P. Vitek. “Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions.Pharmacogenomics, vol. 8, no. 8, Aug. 2007, pp. 959–69. Pubmed, doi:10.2217/14622416.8.8.959.
Laskowitz DT, Vitek MP. Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions. Pharmacogenomics. 2007 Aug;8(8):959–969.
Journal cover image

Published In

Pharmacogenomics

DOI

EISSN

1744-8042

Publication Date

August 2007

Volume

8

Issue

8

Start / End Page

959 / 969

Location

England

Related Subject Headings

  • Polymorphism, Genetic
  • Pharmacology & Pharmacy
  • Pharmacogenetics
  • Nervous System Diseases
  • Inflammation Mediators
  • Humans
  • Cell Death
  • Apolipoproteins E
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences